The Global University Venturing deal net rounds up the smaller investments from across the university innovation ecosystem.
The Global University Venturing deal net rounds up the smaller investments from across the university innovation ecosystem.
The Global University Venturing deal net rounds up the smaller investments from across the university innovation ecosystem.
The small molecule drug developer, co-founded by a UCLA associate professor, has completed its series B round.
The Global University Venturing deal net rounds up the smaller investments from across the university innovation ecosystem.
Exploiting research conducted at Kyoto Prefecture University of Medicine, Aurion Biotech is focusing on therapies that can restore vision.
A roundup of exits, including IPOs and acquisitions, across the tech transfer ecosystem.
The Global University Venturing deal net rounds up the smaller investments from across the university innovation ecosystem.
The metaverse technology developer has now pushed its overall funding past $750m since emerging out of Cambridge’s Department of Computer Science and Technology.
The Global University Venturing deal net rounds up the smaller investments from across the university innovation ecosystem.
The gut microbiome drug developer went public in a $22.5m offering priced at the foot of its range.
The round which pushed the ETH Zurich-linked carbon capture system developer's overall financing past the $800m mark.
The company, which largely remains in stealth mode, has set itself a mission of increasing the human lifespan by a decade.
The Global University Venturing deal net rounds up the smaller investments from across the university innovation ecosystem.
MIT spinout Commonwealth Fusion Systems has raised the largest funding round yet for a nuclear fusion developer with investors including The Engine.
Less than a year after raising $72.6m in its series A round, Aerovate Therapeutics has gone public following an IPO worth more than $121m.
Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Global University Venturing is a quarterly magazine and website written for and about universities taking stakes in the spinout companies of staff and students. We help universities to share best practice and to connect with each other, with investors and with other useful parties in the innovation ecosystem. Our aim is to help improve the processes of bringing innovations from academia to the market and facilitate their integration into the business ecosystem.
